Revenue
2022
2023
2024
2025
Lantern Pharma Inc. (LTRN)
Price$1.86Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — |
| Research & development | $11.5M | $16.1M | $11.9M | $8.6M | $7.6M | $2.2M | — |
| Operating expenses | $18.0M | $22.2M | $17.9M | $14.4M | $12.6M | $5.9M | $2.4M |
| Operating income | −$18.0M | −$22.2M | −$17.9M | −$14.4M | −$12.6M | — | — |
| EBITDA | −$18.0M | −$22.2M | −$17.9M | −$14.4M | −$12.6M | — | — |
| Net income | −$17.1M | −$20.8M | −$16.0M | −$14.3M | −$12.4M | −$5.9M | −$2.4M |
| Basic EPSper basic share | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | -$1.37 | -$1.23 |
| Diluted EPSper diluted share | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | -$1.37 | -$1.23 |
Owners
Reported shareholders
≈8.43%of listed shares
BP Directors, LP / Cavu Advisors, LLC / Kreis Leslie W. / Cavu Management, LP1.08M shares · Jun 13, 2025
View holders
| Holder | % owned |
|---|---|
BP Directors, LP / Cavu Advisors, LLC / Kreis Leslie W. / Cavu Management, LP | ≈8.43%1.08M shares |
Empery Asset Management, LP | 6.60%842.67K shares |
CM Management, LLC | 3.92%500K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.33%425.12K shares |
RENAISSANCE TECHNOLOGIES LLC | 2.28%291.04K shares |
BIOS Capital Management, LP | 1.95%249.4K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.81%102.82K shares |
KEYSER D JEFFREY | ≈0.74%94.3K shares |
VANGUARD FIDUCIARY TRUST CO | 0.39%49.95K shares |
Schalop Lee Troy | ≈0.38%48.54K shares |
CITADEL ADVISORS LLC | 0.38%47.9K shares |
Westside Investment Management, Inc. | 0.38%47.85K shares |
Quadrature Capital Ltd | 0.31%39.59K shares |
NewEdge Advisors, LLC | 0.21%27.05K shares |
HORIZON KINETICS ASSET MANAGEMENT LLC | 0.20%25.16K shares |
DAVENPORT & Co LLC | 0.19%23.81K shares |
STATE STREET CORP | 0.19%23.65K shares |
BlackRock, Inc. | 0.18%22.35K shares |
Bank of New York Mellon Corp | 0.17%21.3K shares |
NORTHERN TRUST CORP | 0.14%17.49K shares |
Percentages use 12.76M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 12, 2026Form 4 | Schalop Lee TroyDirector | BuyCommon stock, $0.001 par value | 48.5K | $2.06 | $100.0K | 48.5K |
| May 12, 2026Form 4 | Schalop Lee TroyDirector | BuyCommon stock purchase warrant (Right to Buy) · derivative | 48.5K | $0.00 | $0.00 | 48.5K |
| May 12, 2026Form 4 | KEYSER D JEFFREYDirector | BuyCommon stock, $0.001 par value | 48.5K | $2.06 | $100.0K | 94.3K |
| May 12, 2026Form 4 | KEYSER D JEFFREYDirector | BuyCommon stock purchase warrant (Right to Buy) · derivative | 48.5K | $0.00 | $0.00 | 48.5K |
| Jun 13, 2025Form 4 | BIOS Fund II QP, LP +9TenPercentOwner | SellCommon Stock · indirect | 4.4K | $3.09 | $13.5K | 114.3K |